Henry Schein (NASDAQ:HSIC) Upgraded at BidaskClub
HSIC has been the subject of several other reports. Craig Hallum downgraded shares of Zayo Group from a buy rating to a hold rating in a report on Wednesday, May 8th. Zacks Investment Research downgraded shares of CGI from a buy rating to a hold rating in a report on Wednesday, June 19th. Cleveland Research reiterated a hold rating on shares of Henry Schein in a report on Thursday, May 2nd. Barrington Research set a $22.00 price target on shares of The Hackett Group and gave the stock a buy rating in a report on Wednesday, May 8th. Finally, Guggenheim started coverage on shares of Patterson Companies in a report on Wednesday, April 17th. They set a neutral rating and a $23.00 price target for the company. Six analysts have rated the stock with a sell rating, ten have issued a hold rating and four have given a buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of $74.13.
NASDAQ:HSIC opened at $67.50 on Thursday. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.65 and a quick ratio of 0.93. The company’s 50-day simple moving average is $69.44. Henry Schein has a twelve month low of $56.58 and a twelve month high of $91.35. The stock has a market cap of $10.06 billion, a P/E ratio of 16.34, a P/E/G ratio of 2.36 and a beta of 0.84.
In other news, VP Walter Siegel sold 4,068 shares of the business’s stock in a transaction on Monday, June 17th. The shares were sold at an average price of $71.29, for a total transaction of $290,007.72. Following the transaction, the vice president now directly owns 48,703 shares of the company’s stock, valued at $3,472,036.87. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Paul Brons sold 1,758 shares of the business’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $70.96, for a total transaction of $124,747.68. Following the transaction, the director now directly owns 17,582 shares in the company, valued at $1,247,618.72. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 49,668 shares of company stock worth $3,572,423. 1.06% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of HSIC. Boston Partners acquired a new position in shares of Henry Schein during the first quarter worth $99,903,000. Norges Bank bought a new stake in shares of Henry Schein in the fourth quarter worth $114,725,000. JPMorgan Chase & Co. increased its stake in shares of Henry Schein by 22.1% in the first quarter. JPMorgan Chase & Co. now owns 2,426,917 shares of the company’s stock worth $145,882,000 after buying an additional 439,922 shares during the last quarter. First Trust Advisors LP increased its stake in shares of Henry Schein by 87.1% in the first quarter. First Trust Advisors LP now owns 868,694 shares of the company’s stock worth $52,217,000 after buying an additional 404,487 shares during the last quarter. Finally, Janus Henderson Group PLC increased its stake in shares of Henry Schein by 31.5% in the first quarter. Janus Henderson Group PLC now owns 1,581,637 shares of the company’s stock worth $95,072,000 after buying an additional 378,634 shares during the last quarter.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Further Reading: What is the definition of a trade war?
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.